About

Mighty Capital is an early-growth Silicon Valley venture capital firm. We look for companies with:
  • a strong leadership team,
  • proven product-market fit, and
  • a clear go-to-market strategy.
We are investors in Digital Ocean, Amplitude and MissionBio. Amplitude calls us the “best value for the dollar invested" and says that our network brought them millions of dollars in revenue. The combination of our diverse partnership expertise and our exclusive access to a global business acceleration platform, Products That Count, helps our portfolio drive sales, hire talent, validate ideas, and exit via corporate M&A. That is why top-tier venture firms like USVP, Mayfield and Aligned Partners invited us to co-invest with them, and why Business Insider says we’ve come up with “a new way of doing venture capital.” If you or someone you know runs a company that meets those criteria, we’d love to hear about it! The best way to get in touch with us is via a mutual connection, most likely a current investor or your law firm. If that’s not an option, then email dealflow@mighty.capital.

Blog


January 2, 2019

The stock market turmoil of December 2018 reminds us to never take anything for granted. Still, good investment opportunities exist if you know where to look. My expectation is that 2019 will see significant private equity and venture capital activity thanks to multiple economic factors including a solid M&A appetite.

Read More

December 14, 2018

Mission Bio delivers targeted single-cell genomics solutions for high-impact applications with Tapestri, the Precision Genomics Platform. Tapestri is the industry’s first targeted single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables, and analysis software, which integrate seamlessly with existing NGS workflows. With Tapestri, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.

Read More

December 11, 2018

In this interview with The Full Ratchet, SC Moatti talks about 13 quick takeaways; including SC’s 3 rules of the most successful products. Explains that “Mobilized” shares examples and case studies implementing those rules.

Read More

December 5, 2018

For Skates, 2018 was an especially momentous year. “I turned 30, we raised a Series D and I got engaged this year,” he said. “That’s going to be hard to top.”

Read More

November 26, 2018
  • Airbnb has hired Amazon VP Dave Stephenson as CFO ahead of its anticipated IPO in 2019.
  • Stephenson spent 17 years as Amazon, most recently as VP and CFO of Amazon’s Worldwide Consumer Organization, responsible for all global website sales. He also spent a couple years as President and CFO of Big Fish Games.
  • Stephenson is the second Amazon exec to join Airbnb this year, following Greg Greeley, who is president of Homes.
Read More

November 19, 2018

Raising a Series A is a huge accomplishment and closing it might feel like you’ve crossed the finish line but the pressure only goes up from here.

Read More

November 8, 2018

Startups working with leading edge technology know that hiring for the most in-demand skills comes with a cost — not just in salary but also in equity grant amounts. The right insight makes reaching your funding goals easier.

Read More

November 6, 2018

We had a lot of fun at our holiday party and are grateful to the investors, entrepreneurs and friends who were able to join us. This is a brief video capturing the vibe of the event.

Read More

October 22, 2018

When VPs, Directors and Managers sit down to negotiate offer terms, there’s a huge gap between West and East Coast outcomes. In Silicon Valley, candidates command 3-4 times the value in new hire grants compared to those out east. Why the difference, and how should startups position themselves accordingly?

Read More

September 25, 2018

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA analysis and precision genomics, today announced a first-of-its-kind study demonstrating its ability to perform single-cell DNA analysis at speed and scale orders of magnitude higher than prior methods. The study, published in Genome Research and co-authored by researchers at Mission Bio and MD Anderson Cancer Center, illustrates its Tapestri platform’s ability to identify the evolution of cellular mutations in Acute Myeloid Leukemia (AML) tumors. This study provides unprecedented insight into the cells that drive complex diseases like cancer and opens the door to the routine sequencing of tumors.

Read More

© 2020 Mighty Capital All Rights Reserved